Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics
Ensho Acquired Rights to Develop and Commercialize EA1080 and Portfolio of Other Oral Selective α4β7 Integrin Antagonists in All Territories…
